Genomic Testing   

Would you sequence tumor-specific treatments first? Where would you sequence non-targeted standard chemotherapy or immunotherapy?

Are you adopting this approach for all patients, patients with PI3K mutations, or none?

Or can we rely on NGS testing to determine eligible patients?

What are the implications of each type of testing for treatment selection?

Will you test HER2 IHC upfront for all? Or wait until later in the disease course, once a patient has exhausted other standard of care options?

Assuming no other actionable mutations.

Per NCCN exclusion of EGFR/ALK alterations at a minimum is recommended prior to consideration of neoadjuvant chemoimmunotherapy.

Should testing for germline mutations -- eg. saliva sample -- occur before or after the completion of chemotherapy - or the timing does not matter?&nb...

If so, what alterations would be helpful to narrow the diagnosis?